vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Wheels Up Experience Inc. (UP). Click either name above to swap in a different company.
Wheels Up Experience Inc. is the larger business by last-quarter revenue ($183.8M vs $183.1M, roughly 1.0× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -15.7%, a 29.0% gap on every dollar of revenue. On growth, Amphastar Pharmaceuticals, Inc. posted the faster year-over-year revenue change (-1.8% vs -10.2%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-58.3M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -3.4%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Wheels Up is a provider of "on demand" private aviation in the United States and one of the largest private aviation companies in the world. It was founded in 2013 by Kenny Dichter, using a membership/on-demand business model. Wheels Up members can book private aircraft from the company fleet and third-party operators using a mobile application.
AMPH vs UP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $183.8M |
| Net Profit | $24.4M | $-28.9M |
| Gross Margin | 46.8% | 14.3% |
| Operating Margin | 19.4% | -0.9% |
| Net Margin | 13.3% | -15.7% |
| Revenue YoY | -1.8% | -10.2% |
| Net Profit YoY | -35.7% | 67.0% |
| EPS (diluted) | $0.51 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $183.8M | ||
| Q3 25 | $191.8M | $185.5M | ||
| Q2 25 | $174.4M | $189.6M | ||
| Q1 25 | $170.5M | $177.5M | ||
| Q4 24 | $186.5M | $204.8M | ||
| Q3 24 | $191.2M | $193.9M | ||
| Q2 24 | $182.4M | $196.3M | ||
| Q1 24 | $171.8M | $197.1M |
| Q4 25 | $24.4M | $-28.9M | ||
| Q3 25 | $17.4M | $-83.7M | ||
| Q2 25 | $31.0M | $-82.3M | ||
| Q1 25 | $25.3M | $-99.3M | ||
| Q4 24 | $38.0M | $-87.5M | ||
| Q3 24 | $40.4M | $-57.7M | ||
| Q2 24 | $37.9M | $-97.0M | ||
| Q1 24 | $43.2M | $-97.4M |
| Q4 25 | 46.8% | 14.3% | ||
| Q3 25 | 51.4% | 6.8% | ||
| Q2 25 | 49.6% | 8.3% | ||
| Q1 25 | 50.0% | 10.8% | ||
| Q4 24 | 46.5% | 13.9% | ||
| Q3 24 | 53.3% | 13.9% | ||
| Q2 24 | 52.2% | 2.3% | ||
| Q1 24 | 52.4% | -0.6% |
| Q4 25 | 19.4% | -0.9% | ||
| Q3 25 | 13.2% | -33.1% | ||
| Q2 25 | 24.2% | -31.4% | ||
| Q1 25 | 21.9% | -45.5% | ||
| Q4 24 | 24.2% | -26.0% | ||
| Q3 24 | 29.8% | -21.6% | ||
| Q2 24 | 30.3% | -40.3% | ||
| Q1 24 | 27.9% | -42.9% |
| Q4 25 | 13.3% | -15.7% | ||
| Q3 25 | 9.0% | -45.1% | ||
| Q2 25 | 17.8% | -43.4% | ||
| Q1 25 | 14.8% | -55.9% | ||
| Q4 24 | 20.4% | -42.7% | ||
| Q3 24 | 21.1% | -29.8% | ||
| Q2 24 | 20.8% | -49.4% | ||
| Q1 24 | 25.1% | -49.4% |
| Q4 25 | $0.51 | $-0.04 | ||
| Q3 25 | $0.37 | $-0.12 | ||
| Q2 25 | $0.64 | $-0.12 | ||
| Q1 25 | $0.51 | $-0.14 | ||
| Q4 24 | $0.74 | $-0.13 | ||
| Q3 24 | $0.78 | $-0.08 | ||
| Q2 24 | $0.73 | $-0.14 | ||
| Q1 24 | $0.81 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $133.9M |
| Total DebtLower is stronger | $608.7M | $671.3M |
| Stockholders' EquityBook value | $788.8M | $-392.1M |
| Total Assets | $1.6B | $968.8M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $133.9M | ||
| Q3 25 | $276.2M | $125.3M | ||
| Q2 25 | $231.8M | $107.0M | ||
| Q1 25 | $236.9M | $171.8M | ||
| Q4 24 | $221.6M | $216.4M | ||
| Q3 24 | $250.5M | $115.9M | ||
| Q2 24 | $217.8M | $141.5M | ||
| Q1 24 | $289.6M | $180.9M |
| Q4 25 | $608.7M | $671.3M | ||
| Q3 25 | $608.6M | $766.5M | ||
| Q2 25 | $607.7M | $770.5M | ||
| Q1 25 | $603.9M | $765.8M | ||
| Q4 24 | $601.6M | $761.3M | ||
| Q3 24 | $596.4M | $596.9M | ||
| Q2 24 | $586.9M | $597.4M | ||
| Q1 24 | $594.0M | $603.2M |
| Q4 25 | $788.8M | $-392.1M | ||
| Q3 25 | $776.7M | $-374.5M | ||
| Q2 25 | $757.5M | $-347.8M | ||
| Q1 25 | $751.3M | $-288.1M | ||
| Q4 24 | $732.3M | $-202.1M | ||
| Q3 24 | $727.7M | $-117.7M | ||
| Q2 24 | $713.3M | $-72.2M | ||
| Q1 24 | $672.4M | $936.0K |
| Q4 25 | $1.6B | $968.8M | ||
| Q3 25 | $1.7B | $973.0M | ||
| Q2 25 | $1.6B | $1.0B | ||
| Q1 25 | $1.6B | $1.1B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.5B | $1.0B | ||
| Q2 24 | $1.5B | $1.1B | ||
| Q1 24 | $1.6B | $1.2B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | 644.43× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $-18.4M |
| Free Cash FlowOCF − Capex | $24.6M | $-58.3M |
| FCF MarginFCF / Revenue | 13.4% | -31.7% |
| Capex IntensityCapex / Revenue | 4.5% | 21.7% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $-259.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $-18.4M | ||
| Q3 25 | $52.6M | $-37.1M | ||
| Q2 25 | $35.6M | $-62.9M | ||
| Q1 25 | $35.1M | $-47.9M | ||
| Q4 24 | $29.0M | $37.9M | ||
| Q3 24 | $60.0M | $-16.9M | ||
| Q2 24 | $69.1M | $-25.2M | ||
| Q1 24 | $55.3M | $-73.8M |
| Q4 25 | $24.6M | $-58.3M | ||
| Q3 25 | $47.2M | $-60.4M | ||
| Q2 25 | $25.0M | $-78.6M | ||
| Q1 25 | $24.4M | $-62.6M | ||
| Q4 24 | $16.6M | $-70.2M | ||
| Q3 24 | $46.2M | $-21.9M | ||
| Q2 24 | $63.1M | $-30.8M | ||
| Q1 24 | $46.5M | $-77.8M |
| Q4 25 | 13.4% | -31.7% | ||
| Q3 25 | 24.6% | -32.6% | ||
| Q2 25 | 14.3% | -41.5% | ||
| Q1 25 | 14.3% | -35.3% | ||
| Q4 24 | 8.9% | -34.3% | ||
| Q3 24 | 24.1% | -11.3% | ||
| Q2 24 | 34.6% | -15.7% | ||
| Q1 24 | 27.1% | -39.5% |
| Q4 25 | 4.5% | 21.7% | ||
| Q3 25 | 2.8% | 12.5% | ||
| Q2 25 | 6.1% | 8.3% | ||
| Q1 25 | 6.3% | 8.3% | ||
| Q4 24 | 6.7% | 52.8% | ||
| Q3 24 | 7.2% | 2.6% | ||
| Q2 24 | 3.3% | 2.9% | ||
| Q1 24 | 5.1% | 2.0% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
UP
Segment breakdown not available.
